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ABSTRACT Adenovirus (Ad) and adeno-associated virus
(AAV) have attractive and complementary properties that can
be exploited for gene transfer purposes. Ad vectors are prob-
ably the most efficient vehicles to deliver foreign genes both in
vitro and in vivo. AAV exhibits the unique ability to establish
latency by efficiently integrating at a specific locus of human
chromosome 19 (AAVS1). Two viral elements are necessary
for the integration at AAVS1: Rep68y78 and the inverted
terminal repeats (AAV-ITRs). In this study, we report the
development of two helper-dependent adenoviral (HD) vec-
tors, one carrying the Rep78 gene, the other an AAV-ITR-
f lanked transgene. Although Rep proteins have been demon-
strated to interfere with Ad replication, HD Rep78 vector was
successfully amplified on serial passages in 293CRE4 cells
with a yield of 50–100 transducing units per cell. DNA
integration at the AAVS1 site also was demonstrated in
hepatoma cells coinfected with the HD-expressing Rep78 and
with the second HD vector carrying a transgene f lanked by
AAV-ITRs. The high transduction efficiency, large cloning
capacity, and high titer of the HD, combined with the site-
specific integration machinery provided by AAV-derived com-
ponents, make the AdyAAV hybrid viruses a promising vehicle
for gene therapy.
Vectors based on different viruses have been developed to
embrace a wide range of strategies for the gene therapy of a
variety of diseases (1). Preclinical evaluation of many of these
approaches has revealed a number of fundamental problems.
These limitations are driving vector technology efforts toward
a further evolution of the present systems and the generation
of new classes of vectors that combine the best features of
different viruses (2–5). The modification of recombinant ad-
enovirus (Ad) vectors is an example of vector engineering
directed to solving problems identified by preclinical studies.
Ad is considered an attractive vehicle for several reasons. The
viral life cycle is well characterized, its genome is easy to
manipulate, and the resulting vector can be grown to high titers
(6). In addition, Ad has a broad tropism and can infect both
dividing and nondividing cells. However, studies with E1-
deleted Ad vectors have shown that (generally) only short-term
expression of the transgene can be achieved (7). Administra-
tion of high titer Ad vectors to nonhuman primates has been
associated with severe host inflammatory responses (8) and
immune clearance of transduced cells thought to be, at least in
part, a consequence of leaky expression of Ad early and late
genes (9, 10). Deletion or mutation of additional viral genes
and parallel development of complementing cell lines is one
approach proposed to overcome the problem of vector immu-
nogenicity (11, 12). The most recent advance is the develop-
ment of a helper-dependent (HD) Ad gutless vector (13–18).
In this system a helper virus provides in trans all of the viral
proteins required for propagation of the vector, which contains
only the inverted terminal repeats (ITRs) and packaging signal
required for DNA replication and virus assembly. These two
elements are contained within about 500 base pairs located at
the ends of viral genome allowing the cloning of up to 37 kb
of foreign DNA. Recently, Graham and coworkers (17) de-
veloped an efficient system for HD vector propagation based
on a helper virus that includes a packaging signal f lanked by
loxP sites and a 293 cell line expressing Cre recombinase.
Although deletion of all coding regions should solve many
of the problems related to immunogenicity of Ad vectors (19,
20), vector DNA is expected to persist extrachromosomally in
nuclei of transduced cells. Therefore, Ad-mediated gene de-
livery to tissues with rapid regeneration is likely to lead to loss
of the transgene. The adeno-associated virus (AAV) life cycle
suggests a potential solution to this problem. AAV is a human
parvovirus dependent on Ad for replication and propagation
(21) and, in the absence of helper virus, AAV establishes
latency by frequently integrating into a specific locus of
chromosome 19, called AAVS1 (22, 23). Two AAV elements
are required for viral DNA integration: the ITRs and either of
the two larger Rep polypeptides, Rep68 and Rep78 (24–26).
These two polypeptides are derived by transcription from the
P5 promoter, whereas the smaller Rep proteins, Rep52 and
Rep40, are derived from transcription from the P19 promoter
(21). This unique property of AAV has stimulated consider-
able efforts toward the development of AAV-based vectors in
which the viral genes encoding the replication functions as well
as the structural polypeptides have been substituted by the
gene of interest. Recombinant AAV vectors (rAAV) in which
rep has been deleted cannot, however, integrate in the AAVS1
locus (27), but several groups have recently demonstrated that
site-specific integration can occur if Rep protein(s) is provided
in trans (24–26, 28, 29).
Incorporating the AAV integration machinery into Ad
vectors would combine advantages of both viral systems.
Although transgenes flanked by AAV-ITRs can be easily
inserted into Ad vectors, the rescue of Ad viruses carrying rep
gene is more problematic. Efforts to construct an Ad vector
expressing Rep protein(s) have been unsuccessful so far,
presumably because Rep inhibits Ad replication (30). We
report here the successful construction of an AdyAAV hybrid
virus system consisting of the combination of two HD vectors:
the first expressing AAV Rep78 gene under control of either
the T7 or a1antitrypsin (a1at) liver-specific promoter, the
second carrying an AAV-ITR-flanked DNA.
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Tissue Culture and Virus Growth. The 293CRE4 cell line
(31) was propagated in minimal essential medium (MEM)
supplemented with 10% fetal calf serum and 0.4 mgyml G418.
HepG2, Hep3B, Huh7, and HeLa cells were grown in DMEM
supplemented with 10% fetal calf serum. Ad2 virus and
AdLC8cluc helper virus (17) was amplified and titrated on 293
cells as described (32).
Construction of AdyAAV Hybrid Viruses. Plasmids were
constructed according to standard protocols (33). The rep 78
gene was derived as described (34) by mutating the ATG start
codon for Rep 52y40 to GGA (methionine 3 glycine, amino
acid 225) and creating a G 3 A mutation at nucleotide 1,907
to eliminate the splice donor site required for expression of
spliced versions Rep 68y40. RepDATG mutants were obtained
by PCR designed to delete the first ATG of the rep ORF.
A T7 promoter fused to an upstream synthetic transcription
pause site was isolated by PCR amplification from pCAT-3
(Promega) then ligated to Rep or Rep78 (nucleotides 321–
2,252 of AAV-2) and to the corresponding DATG mutant
cassettes and inserted in the shuttle plasmid pABS-4 (35),
generating pABT7-Rep78, pABT7-Rep, pABT7-Rep78-
DATG, and pABT7-RepDATG. To construct the first gener-
ation vectors carrying rep genes, a PacI fragment from these
four plasmids containing the T7-Rep cassettes was ligated into
the unique PacI site located in the E3 region of pLBG40.
Plasmid pLBG40 (N. Louis and F. L. Graham, unpublished
results) contains an Ad5 genome deleted in E1 and E3 regions
allowing insertion of up to 6 kb of foreign DNA by direct
cloning into either the E1 or E3 region and pLBG40 is
infectious when transfected in 293 cells as the parental plasmid
pFG140 (36).
HD vectors carrying the Rep78 gene were constructed in the
context of pRP1030 Ad helper-dependent plasmid. pRP1030
was derived from pRP1001 (17) by deleting all Ad5 coding
sequences and substituting them with l phage DNA (22,425-bp
BglII fragment) to produce a genome of packageable size (Fig.
1) (37). T7-Rep78 or T7-Rep78DATG cassettes were ligated
into the unique StuI site of the l DNA stuffer, generating the
plasmids pRS1033 and pRS1032, respectively. The cassette
comprising D137a1at promoter (38) fused to Rep78 gene was
constructed in the shuttle plasmid pABS-4 following the
reported cloning strategy and then inserted in the StuI site of
pRP1030 obtaining pRP1034. Finally, HDFB1 was derived
from pSTK120 (a gift of S. Kochanek, University of Cologne)
following the strategy reported below. A transgene cassette
containing the green fluorescent protein (GFP) and hygromi-
cin B resistance genes flanked by AAV-ITR sequences was
derived from pBac-ITR plasmid (4) by replacing lacZ with
GFPyUF5 gene excised from pITR-UF5 plasmid (kindly ob-
tained by N. Muzyczka, University of Florida). The AAV-
ITR-flanked cassette was then inserted into the SmiI site of
pSTK120, generating pSTK-FB1. HDFB1 was rescued by PmeI
restriction from pSTK-FB1 before transfection. STK120 plas-
mid is a pBluescript II KS that contains (in the following order)
the Ad5 ITR sequences and the packaging signal C, 440 bp
(nucleotides 1–440 of Ad5); a 16,054-bp fragment of hypo-
xanthine guanine phosphoribosyltransferase (nucleotides
1,799–17,853 in gb:humhprtb); a HindIII 9,063-bp fragment of
C346 cosmid (nucleotides 12,421–21,484 in gb:L31948); the
right-end terminus of Ad5, 117 bp (nucleotides 35,818–35,935
of Ad5); and the pBluescript II KS plasmid sequence. Further
details of vector construction are available on request.
Propagation of AdyAAV Hybrid Viruses. To rescue the first
generation AdyAAV hybrid vectors, 60-mm dishes of a semi-
confluent monolayer of 293 cells were transfected with 5 mg
each of pLBG40 derivatives, and plaques were isolated and
processed by standard methods (32).
HD vectors were propagated and purified as described by
Parks et al. (17). Rescue and amplification of HD vector were
performed on 293CRE4 cells preinfected with AdLC8cLucl
helper virus. Amplification of b-gal-expressing viruses was
monitored as described (17). Large-scale virus preparations
were obtained by infecting 150-mm dishes of 293CRE4 cells at
a multiplicity of infection (moi) of 1 transducing unit per cell
of HDs on preinfection with the same moi of helper virus. The
virus was purified as described (32).
To evaluate the efficiency of AdyAAV hybrid viruses,
rescue and replication assay was performed by infecting 293 or
FIG. 1. (A) Schematic representation of vector structures. All rep
cassettes were constructed and inserted in the helper-dependent
plasmid pRP1030 as outlined in Materials and Methods. Mutation of
Rep52y40 ATG to GGA, G 3 A mutation of splice donor site, and
deletion of first Rep78 ATG (respectively nucleotides 993–996, 1,907,
and 321–323 of AAV-2) were reported on the vector diagrams.
pRP1030 (shown in linear form) contains sequences corresponding to
left ends (base pairs 3–466) and to the right end (base pairs 35,464–
35,924) of Ad5 genome including ITRs and packaging signal. All other
Ad5 genomic sequences were deleted and substituted with a mouse
cytomegalovirus immediate early promoter (MCMV)-lacz cassette
that corresponds to nucleotides 467–4,920 of pRP1030, a 22,425-bp
BglII fragment of l DNA (nucleotides 5,128–27,138). A bacterial
plasmid (pMX2) is present between nucleotides 27,138 and 29,373. (B)
Serial amplification of Hd-Rep vectors. pRP1030 was amplified as
positive control. All plasmids were converted to linear molecules and
packaged into infectious virions after transfection of 293CRE4 cells
infected with AdLC8 helper virus. Amplification was measured by 293
infection with aliquots of 293CRE lysate and b-galactosidase staining.
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Hep3B cells with Rep-expressing viruses in combination with
HDFB1. Wild-type Ad2 was included as helper virus when the
experiments were performed with HD vectors in Hep3B cells.
Total cellular DNA was extracted 48 hours postinfection with
standard techniques and analyzed by Southern blot using a
hygromicin B DNA-specific probe (see Fig. 3B).
PCR Assay for AAVS1 Integration. HepG2, Hep3B, and
Huh7 cells were coinfected at an moi of 10 blue-forming units
(bfu)ycell with HDRS1032 or HDRA1034 in combination
with HDFB1 at an moi of 10 transducing units per cell. Cells
were harvested by scraping 48 hours after infection, and total
DNA was extracted by using standard techniques (33). Nested
PCR was performed as described (25). One-tenth of the
amplified DNA was loaded in duplicate on a 1.3% agarose gel,
electrophoresed, transferred to Hybond N1 membrane (Am-
ersham Pharmacia), and hybridized with AAVS1 or AAV-
ITR-specific probes.
Fluorescence in Situ Hybridization. A 3.7-kb DNA fragment
corresponding to the ITR(GFPyHygro) cassette and a 80-kb
AAVS1 DNA fragment isolated from a genomic DNA library
were labeled using nick-translation kit (Boehringer Mann-
heim) according to the manufacturer’s instruction and used as
probes in chromosome analysis. The chromosome spreads
from a pool of hygromicin-resistant HepG2 cells were pre-
pared by standard cytogenetic techniques (39). Cytogenetic
preparations were treated as described (4). Images were
processed by using Adobe Photoshop on a Power Macintosh
computer (Apple).
RESULTS AND DISCUSSION
Rescue and Amplification of AdyAAV Vectors Expressing
rep Gene. Different studies on the relationship between Ad and
AAV demonstrated a strong interference of AAV on Ad life
cycle (40–42). Although the molecular mechanism of AAV-
mediated inhibition is not clear, Wilson and coworkers (30)
have demonstrated that Rep expression is sufficient to sup-
press the maturation of Ad replication centers. In view of the
observation that the P5 promoter, which drives the expression
of Rep68 and Rep78 (21), is transactivated by Ad E1A proteins
(43, 44), we reasoned that replacement of P5 with the phage
T7 promoter could reduce Rep expression during virus
growth, thus minimizing Rep-mediated interference on Ad
vector replication. The T7 promoter has been used to rescue
a recombinant Ad expressing the highly toxic virion host
shutoff protein of Herpes simplex (R. Tomanin, M. Rosa, and
F.L.G., unpublished results). Rep expression cassettes were
constructed by fusing the T7 promoter to the wild-type rep and
rep78 genes and inserting them into the infectious Ad plasmid
pLBG40 (see Materials and Methods). As control, the corre-
sponding DATG mutant plasmids were also constructed. Sur-
prisingly, as shown in Table 1 no plaques were obtained by
transfecting either pLBT7-Rep or pLBT7-RepDATG. It is
worth noting that the deletion of the first ATG introduced into
the rep coding sequence is expected to abolish expression of
full-length Rep78 and Rep68, but not of p19-promoted Rep52
and Rep40 (45). In contrast, pLB-Rep78 was successfully
rescued, albeit with a lower efficiency than pLBT7-
FIG. 2. Western blot analysis of protein extracted from HeLa and
Hep3B cells infected with Rep78-expressing Ad vectors. Cells (1.2 3
106) were infected with HDRA1034 or HDRS1032 at an moi of 50
bfuycell. An AAV-infected 293 cell extract was included in the
experiment as positive control. Cell extracts equivalent to 3 3 105 cells
were separated on 7.5% SDSyPAGE and transferred to nitrocellulose
membrane. Rep polypeptides were detected with a polyclonal rabbit
antiserum and chemiluminescence kit (ECL; Amersham Pharmacia).
Rep78 polypeptide is indicated on the right margin. A cross-reacting
protein of slightly lower molecular weight of Rep78 was detected in
some experiments.
FIG. 3. Structure of HDFB1 and evaluation of Rep78 expression
by AAV-ITR-flanked transgene rescue and replication. (A) HDFB1
carries an integration cassette constituted by hygromicin resistance
and GFP genes flanked by AAV-ITRs and was constructed as outlined
in Materials and Methods. (B) Hep3B cells were infected with an moi
of 10 transducing units per cell of HDFB1 (lanes 1–3) in combination
with HDRA1034 (lane 1) or HDRS1032 (lane 2) at an moi of 10.
Infection with HDFB1 alone served as negative control (lane 3).
Rescue and replication experiment was carried out infecting the cells
with Ad2 wild type (moi 5 10) as helper virus. Total cellular DNA was
separated on agarose gel, transferred on nylon membrane, and hy-
bridized with an HygroR DNA-specific probe. Signals corresponding
to ITR(GFP/Hygro) cassette monomer, dimer, and HDFB1 whole
genomic DNAs are indicated.




pLBT7-Rep 0 0 ND
pLBT7-Rep78 4 6 1
pLBT7-RepDATG 0 0 ND
pLBT7-Rep78DATG 15 18 2
Control 22 26 2
Data given as number of plaques obtained. Plaques were observed
10 days after 293 transfection. Plaque isolates were amplified through
four serial passages on 293 cells and then evaluated for Rep activity in
rescue and replication experiments as described in Materials and
Methods. All AdLBT7-Rep78 isolates were positive for Rep enzymatic
activity. ND, not determined.
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Rep78DATG and pLBG40 control plasmid. No rearragement
of the genomic DNA was detected in LBT7-Rep78 virions.
Furthermore, the functionality of the Rep78 polypeptide was
demonstrated by coinfection of 293 cells with AdLBT7-Rep78
and the HD vector HDFB1 (Table 1). This virus carries an
AAV-ITR-flanked DNA (Fig. 3A) that was rescued and
amplified on expression of Rep78. Taken together, these data
indicate that Rep78 is compatible with Ad replication and that
Rep mediated interference on Ad replication could be reduced
by replacing the P5 promoter and abolishing the expression of
other Rep polypeptides.
To exploit the potential of the HD vectors for gene transfer,
the T7Rep78 expression cassette was inserted into the Ad
helper dependent plasmid pRP1030 (Fig. 1A), generating
pRS1033. Similarly, plasmid pRA1034 was constructed by
fusing the Rep78 coding sequences to the D137a1at promoter
(38). This promoter is poorly active in 293CRE cells (C.T.,
unpublished data) and thus is expected to minimize Rep78
expression during vector amplification. As control, plasmid
pRS1032 carrying T7Rep78DATG was also constructed. Fig.
1B shows the efficiency of amplification of the HD-Rep vectors
evaluated as bfuyml. Little or no difference in rescue and
amplification efficiency was observed between the control
vector HDRP1030 and its rep derivatives. Additionally, the
time course of CPE during vector propagation was not affected
by infection with HD-Rep viruses and was usually complete by
48 to 72 hrs postinfection, suggesting that the overall Ad life
cycle had not been perturbed. A large-scale preparation of
HDRA1034 resulted in the production of 3 3 109 bfu from 5 3
107 cells, indicating that 50–100 Rep-expressing viruses per cell
could be produced without interference. Furthermore, no
apparent rearrangement of virus genome had occurred on
vector amplification, as indicated by Southern blot analysis of
HDRS1034 and HDRS1032 genomic DNA (data not shown).
The expression of Rep78 was assessed by infecting Hep3B
and HeLa cells with an moi of 50 bfuycell of HDRA1034 or
HDRS1032. Cells were harvested 36 hours postinfection, and
Western blot analysis by using a rabbit anti-Rep antiserum was
performed on infected cell lysates (Fig. 2). A cell extract of 293
cells infected with AAV was used as positive control. As
expected, Rep78 expression was detected only in Hep3B
infected with HDRA1034. The functionality of Rep78 ex-
pressed by HDRA1034 was evaluated by exploiting the ability
of this protein to rescue an ITR-flanked DNA and to support
its replication in Ad-infected cells (46). Hep3B cells were
coinfected with HDFB1 (Fig. 3A) in combination with
HDRA1034 by using as helper Ad2 wild-type virus. Infection
was carried out using an moi of 10 for each virus. Total DNA
was extracted and analyzed 48 hr postinfection by Southern
blot by using a DNA probe specific for the transgene. As shown
in Fig. 3B, the presence of low molecular weight DNA bands
corresponding in size to the monomer and dimer forms of the
replicated AAV-ITRytransgene cassette were detected in
HDFB1-infected cells coinfected with HDRA1034 vector (Fig.
3B, lane 1). No rescue of the ITR-flanked cassette was
detected in cells that were infected with HDFB1 alone or
coinfected with HDRS1032 (Fig. 3B, lanes 2 and 3). Thus,
these data indicated that HDRA1034 encodes a fully func-
tional Rep78 protein.
Site-Specific Integration of an AAV-ITR Transgene. To
assess whether Rep-mediated targeted integration could be
observed on infection with HD vector expressing Rep78,
Hep3B cells were coinfected with HDRA1034 and HDFB1.
Forty-eight hours postinfection, cells were harvested, genomic
DNA was extracted, and a nested PCR-based assay on genomic
FIG. 4. PCR amplification of AAVS1-AAV-ITR junction. (A) Southern blot analysis of amplification products obtained by using DNA extracted
from infected cells as template. Total DNA was isolated from Hep3B cells infected with HDFB1 (moi 5 10 transducing units per cell) alone (lanes
3 and 7) and in combination with HDRA1034 (lanes 1 and 5) or HDRS1032 (lanes 2 and 6) (moi 5 10 bfuycell). DNA from mock-infected cells
is shown in lanes 4 and 8. Nested PCR amplification was performed as described in ref. 25. One-tenth of the PCR reaction was loaded on 1.2%
agarose gel in duplicate, transferred to nylon membrane, and hybridized with two different probes derived from AAVS1 or AAV-ITR DNAs. (B)
Amplified DNA was cloned and sequenced. The junction DNA sequences reported represent the most frequent clones obtained in different
experiments performed in Hep3B, Huh7, and HepG2 cell lines. Sequences not belonging to ITR or AAVS1 are in lower case letters.
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DNA was performed to detect junctions between AAVS1 and
AAV-ITRs (24, 25). Two pairs of primers specific for AAVS1
and AAV-ITRs were used, the AAVS1 primers annealed to a
region located downstream the 100-bp AAVS1 region identi-
fied as ‘‘hot spot’’ for site-specific integration (23). The
amplification products were identified as the junction frag-
ments by virtue of their hybridization to AAVS1- and ITR-
specific probes. Fig. 4A shows the results obtained on coin-
fection of Hep3B cells. Similar results were obtained by using
other cell line of hepatic origin (data not shown). Three bands
between 400 bp and 220 bp superimposed on a smear (with the
major species being approximately 220 bp) were detected only
in cells infected with HDFB1 and HDRA1034 (Fig. 4A, lanes
1 and 5). No junctions were amplified from mock-infected cells
(Fig. 4A, lanes 4 and 8) or from cells infected with HDFB1
alone or with HDRA1032 (Fig. 4A, lanes 2 and 6 and 3 and 7,
respectively). To better characterize the AAV-ITRyAAVS1
junctions, amplified DNA was cloned and sequenced. The
sequences of the most frequently isolated clones are shown in
Fig. 4B. The junctions analyzed indicated that insertion of the
ITR-flanked DNA had occurred at nucleotids 980, 1,027, and
1,034 of AAVS1 in Huh7, Hep3B, and HepG2, respectively.
Additionally, deletions within the ITRs and insertions of
nucleotides were detected.
Different studies demonstrate that transduction of 293 cells
with vectors carrying the rep gene and a reporter gene inserted
between AAV-ITRs lead to a highly efficient integration of the
ITR-flanked DNA (4, 24, 28). To verify whether the delivery
of AAV components mediated by the HD vectors can establish
more stable cell clones also in hepatic cells, 1 3 105 Hep3B
cells were infected with HDFB1 alone or in combination with
HDRA1034 at a moi of 10. Cells were diluted 48 hr postin-
fection and cultivated in the presence of 100 mgyml hygromicin
B. Stable integration frequency was evaluated by comparing
the number of clones obtained in the presence and absence of
Rep78 expression. An average of 400 stable transformants
were obtained on coinfection of the two vectors, whereas 600
hygromicin B-resistant clones were detected after infection
with HDFB1. Similar results were obtained on infection of
HepG2 and Huh7 cells (data not shown). The lack of a
Rep78-mediated increase in stable transformants in hepatic
cells was apparently not caused by any toxic effects on host cells
mediated by constitutive expression of Rep78. In fact, no
differences in Hep3B viability were noted in a cell proliferation
assay between uninfected Hep3B and cells infected with
HDRA1034 at a moi of 1, 10, and 100. These results suggested
that the increased integration efficiency of an ITR-flanked
DNA mediated by Rep is restricted to 293 cells. It is very likely
that specific host factors preferentially expressed in these cells
may influence the frequency of Rep-mediated integration.
To determine the efficiency of site-specific integration, in
situ hybridization studies were performed on chromosomes of
infected cells. Stable clones were obtained by infecting HepG2
cells with 5 bfuycell of HDRA1034 or HDRS1032, the lowest
moi compatible with infection of 80–90% of the cell popula-
tion, in combination with the same moi of HDFB1. Infected
cells were passaged several times in presence of 150 mgyml
hygromicin B, and fluorescence in situ hybridization analysis
was then performed on metaphase spreads by using AAVS1-
and hygromicin B-specific probes. Double labeling on both
sister chromatids was scored as a positive signal for site-specific
integration. In HepG2 cells infected with HDRA1034 and
HDFB1, targeted integration to the AAVS1 site was observed
in 14 of 39 (35%) metaphases analyzed, whereas only one
integration in chromosome 19 was observed in 34 metaphases
(3%) of cells infected with HDRS1032 and HDFB1. Fig. 5
shows a metaphase spread in which the transgene probe
colocalized with the AAVS1 probe in one of the three
chromosomes 19 present in this cell line. The transgene was
always associated with only one chromosome 19 in all positive
metaphase spreads examined, whereas in the remaining met-
aphases the transgene probe was located on different chro-
mosomes that were not detected by the AAVS1 probe (data
not shown). Taken together, the analysis of the stable trans-
duction capacity of the AdyAAV hybrid vectors and the in situ
hybridization study indicate that Rep expression increases
targeted insertion of AAV-ITR-flanked DNA without affect-
ing the overall integration frequency in cells of hepatic origin.
We report in this study the construction of AdyAAV hybrid
vectors that express functional Rep78 protein, the major
trans-acting component of the AAV integration machinery.
Several features might have contributed to reach this goal: (i)
the Rep cassette used was designed to express only Rep78; (ii)
the substitution of P5 with promoters poorly expressed in
293CRE cells have further reduced Rep78 production in the
packaging cell line; and (iii) the helper-dependent packaging
system has introduced amplification conditions that are likely
to minimize Rep interference of vector production. Indeed,
AAV-mediated inhibition of Ad replication depends on the
ratio of the moi of the two viruses and on the temporal order
in which each virus is added (35, 36). Furthermore, it has been
reported that if AAV infection is delayed until Ad DNA
replication has begun, AAV does not interfere with Ad
replication (36). These observations may account, at least in
part, for the fact that a HD vector carrying Rep78 could be
amplified during consecutive rounds of coinfection with helper
virus without significant differences from the control viruses.
The mechanism by which rep gene expression interferes with
Ad replication is not clear. However, our results with first-
generation Ad vectors carrying rep gene suggest that P19-
promoted Rep52 and Rep40 gave an important contribution to
Ad replication inhibition. The biochemical properties of the
Rep78–68 polypeptides and their role in AAV replication
have been studied in detail. They are multifunctional proteins
with DNA binding, site-specific endonuclease, helicase, and
ATPase activity (47, 48). In contrast, little is known about the
functions of Rep52y40 proteins. Recently, Rep52 was identi-
fied as a DNA helicase with ATPase activity displaying distinct
FIG. 5. Fluorescence in situ hybridization of metaphase spreads
from a pool of HepG2 selected in the presence of hygromicin B. Cells
were selected on coinfection with HDRA1034 and HDFB1, a helper-
dependent vector carrying ITR(GFPyHygro) cassette. Metaphase
spreads were hybridized following the conditions described in ref. 4
with a GFPyhygromicin (red) and an AAVS1 probes (yellow). Colo-
calization of both probes on chromosome 19 is indicated by an arrow.
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biochemical characteristics with respect to those of Rep78 and
Rep68 (49). The fact that rep gene encodes two different
families of helicase proteins may suggest that Rep proteins are
likely to influence Ad replication by interacting directly with
the Ad genome. However, further investigation will be re-
quired to identify the step of Ad life cycle affected by Rep
protein.
Recently, several hybrid viruses carrying AAV elements
relevant for site-specific integration have been constructed,
including baculovirusyAAV (4), herpes simplexyAAV (3), and
E1-deleted Ad vector coupled to a plasmid expressing Rep (2).
The HDyAAV hybrid vectors may offer several potential
advantages over other vector systems, which include high titers
and efficient in vivo gene transduction. The strategy we used
to obtain site-specific integration was based on coinfection of
target cells with two different viruses. We are now exploring
the possibility of including both rep and AAV-ITR-flanked
transgene in a single vector. According to the proposed model
for rescue of AAV genome from integrated state (50), vector
instability during amplification can be predicted if a constitu-
tively active rep gene is used (4). We are currently modifying
our vector system to provide a more stringent control of Rep
expression, which may be crucial to improve production,
transduction efficiency, and integration specificity. These new
hybrid AdyAAV vectors will broaden our spectrum of tools for
the understanding of the molecular mechanisms that govern
Rep-mediated targeted integration.
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